Susan Galloway Hilsenbeck, Ph.D.

Professor

(713) 798-1627

Email

sgh@bcm.edu

Positions

Professor: Smith Breast Center - Hilsenbeck
Baylor College of Medicine
Houston, TX, US

Director, Quantitative Sciences Share Resource: Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas, United States

Addresses

BCM-Cullen Building (Office): Room: BCMC-333A
Houston, TX, 77030
United States

Education

Ph.D. from University Of Miami: 01/1990 - Miami, FL, United States

Certifications

Fellow: American Statistical Association

PStat: American Statistical Association; Certified Professional Statistician

Fellow: (02/17/2025); Academy of the American Association for Cancer Research

Professional Interests

Design and statistical analysis of translational experiments and clinical trials

Professional Statement

Dr. Hilsenbeck has a PhD in applied biostatistics, and has long-standing interests in biostatistical and informatics collaboration, especially in cancer research. She is the statistician of record on a number of investigator-initiated multi-center clinical trials and leads several of the biostatistics and informatics focused resources at Baylor, including: Quantitative Science Shared Resource, Duncan Comprehensive Cancer Center; and Biostatistics and Informatics, Advanced Technology Cores at BCM.
Dr. Hilsenbeck's personal research interests focus on design and analysis of prognostic and predictive biomarker studies. She is also committed to teaching. She serves on mentoring committees, leads the required biostatistics course for biomedical graduate students, and is regularly invited to teach in national and international workshops.

Websites

NCBI Bibliography

ORCID

Selected Publications

Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. " Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. " 2016 ; 22 : 4291-4301.
Pubmed PMID: 27407096.
Hertz DL, Kidwell KM, Hilsenbeck SG, Oesterreich S, Osborne CK, Philips S, Chenault C, Hartmaier RJ, Skaar TC, Sikora MJ, Rae JM.. " CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study. " Breast Cancer Res Treat.. 2017 ;
Pubmed PMID: 28730340.
Mo Q, Shen R, Guo C, Vannucci M, Chan KS, Hilsenbeck SG.. " A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. " Biostatistics. 2017 ;
Pubmed PMID: 28541380.
Musher BL, Rowinsky EK, Smaglo BG, Abidi W, Othman M, Patel K, Jawaid S, Jing J, Brisco A, Leen AM, Wu M, Sandin LC, Wenthe J, Eriksson E, Ullenhag GJ, Grilley B, Leja-Jarblad J, Hilsenbeck SG, Brenner MK, Loskog ASI.. " LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study. " Lancet Oncol. 2024 ; 25 (4) : 488-500.
Pubmed PMID: 38547893.
Parker SL, Amboree TL, Bulsara S, Daheri M, Anderson ML, Hilsenbeck SG, Jibaja-Weiss ML, Zare M, Schmeler KM, Deshmukh AA, Chiao EY, Scheurer ME, Montealegre JR.. " Self-Sampling for Human Papillomavirus Testing: Acceptability in a U.S. Safety Net Health System " Am J Prev Med.. 2024 ; 66 (3) : 540-547.
Pubmed PMID: 37935320.
Veeraraghavan J, Gutierrez C, De Angelis C, Davis R, … Nangia JR, Wolff AC, Weigelt B, Reis-Filho JS, Hilsenbeck SG, Prat A, Osborne CK, Schiff R, Rimawi MF.. " A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. " Clin Cancer Res.. 2023 ; 29 (16) : 3101-3109.
Pubmed PMID: 37195235.

Memberships

American Statistical Association: Member

American Association for Cancer Research: Member

American Society for Clinical Oncology: Member